We provide targeted DNA sequencing allowing us to focus specific areas of interest at a reduced price and faster delivery time. Our laboratory’s technology can accommodate small blood sample sizes, making it viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health.
NEXT GENERATION SEQUENCING – GERMLINE MUTATION
Our Cystic Fibrosis 139-Variant Assay is a FDA cleared genetic testing assay. It is a qualitative in vitro diagnostic test that detects 139 clinically relevant cystic fibrosis disease-causing mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.
The test is intended for carrier status testing in adults of reproductive age, followed by confirmatory diagnostic testing of newborns and children. It is also used as a diagnostic test for individuals suspected to have cystic fibrosis.
All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC) is a CLIA certified laboratory. If you have any questions about Genetic Testing Next Generation Sequencing at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.
No announcement available or all announcement expired.